News · 26 weeks21+100%
2026-04-192026-10-11
Mix1190d
- Other6(55%)
- SEC Filings5(45%)
Latest news
25 items- PRImmutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 ResearchSYDNEY, AUSTRALIA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce that the Australian Research Council (ARC) has awarded Monash University a grant of A$652,248 over three years under the ARC’s Linkage Projects scheme to support its continuing research collaboration with Immutep into Lymphocyte Activation Gene-3 (LAG-3). The ARC Linkage Projects scheme is highly competitive and supports collaborations between Australian researchers and industry partners that address significant research challenges and deli
- SECSEC Form 6-K filed by Immutep Limited6-K - IMMUTEP Ltd (0001506184) (Filer)
- PRImmutep Regains Compliance with Nasdaq Minimum Bid Price RequirementSYDNEY, AUSTRALIA, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), dated 12 October 2026 (US Eastern Time), confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). Nasdaq determined that the closing bid price of the Company's American Depositary Shares ("ADSs") was at or above US$1.00 per ADS for 10 consecutive business days, from 28 September
- PRImmutep Receives ~A$0.86 Million R&D Tax IncentiveSYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A$856,669 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate was provided in respect of expenditure incurred on eligible R&D activities conducted in the 2025 fiscal year. This follows approval from AusIndustry of Immutep’s application for an Advance overseas finding. Due to the Advance overseas finding, certain of Immutep’s overseas research and development activities were eligible for the R&D Tax Incentive, in
- SECSEC Form 6-K filed by Immutep Limited6-K - IMMUTEP Ltd (0001506184) (Filer)
- PRChange to American Depositary Share RatioSYDNEY, AUSTRALIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces a change to the ratio of its American Depositary Shares ("ADSs"), which are quoted on the Nasdaq Global Market under the symbol IMMP. With effect from the commencement of trading on the Nasdaq Global Market on 28 September 2026 (US Eastern time), the ADS ratio will change from one (1) ADS representing ten (10) ordinary shares to one (1) ADS representing two hundred (200) ordinary shares. For holders of ADSs, the change has the same practical effect as a reverse split of the
- SECSEC Form 6-K filed by Immutep Limited6-K - IMMUTEP Ltd (0001506184) (Filer)
- PRImmutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)Future registration-directed clinical development of efti is intended to focus on head and neck squamous cell carcinoma (HNSCC) in patients with negative PD-L1 expression (Combined Positive Score (CPS) < 1) and the neoadjuvant setting of soft tissue sarcoma (STS).Root cause analysis following the discontinuation of TACTI-004 has identified subtle analytical differences between efti manufactured at 200 L scale and efti manufactured at 2,000 L scale. A new manufacturing run of efti at 200 L scale has been contracted.This development focus reflects a staged risk/benefit approach consistent with prior interactions with the U.S. Food and Drug Administration (FDA), Orphan Drug Designation granted
- SECSEC Form 6-K filed by Immutep Limited6-K - IMMUTEP Ltd (0001506184) (Filer)
- SECSEC Form 6-K filed by Immutep Limited6-K - IMMUTEP Ltd (0001506184) (Filer)
- PRImmutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026SYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that an abstract for the investigator-initiated EFTISARC-NEO Phase II trial evaluating its first-in-class MHC Class II agonist, eftilagimod alfa ("efti"), has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place 23–27 October 2026 in Madrid, Spain. The abstract reports health-related quality of life (HRQoL) data from EFTISARC-NEO. Details of the accepted abstract and poster are as follows: TitleHealth-related quality o
- PRImmutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway InhibitorSYDNEY, AUSTRALIA, July 14, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapies, today announced the grant of a new patent (number 12,673,088) entitled "Combined Preparations for the Treatment of Cancer or Infection" by the United States Patent and Trademark Office (USPTO). This patent is the fourth in the series and follows the grant of the United States parent patent, first divisional patent, and second divisional patent announced in December 2020, March 2021 and June 2023, respectively. The claims of the new patent build on the protection provided by the three previously granted patent
- SECSEC Form 6-K filed by Immutep Limited6-K - IMMUTEP Ltd (0001506184) (Filer)
- PRImmutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004INSIGHT-003 demonstrates mature mOS of 30.9 months in both the overall population (N=51) and patients with TPS <50% (N=47) in 1L non-squamous NSCLCOutcomes continue to compare favourably with historical benchmarksPreliminary immune monitoring data indicate that patients treated with efti in TACTI-004 exhibited a different immune activation profile compared with previous studies TACTI-004 root cause analysis is ongoing with additional results expected in Q3 CY2026 SYDNEY, AUSTRALIA, July 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapies, today announced a significant positive update o
- SECSEC Form 6-K filed by Immutep Limited6-K - IMMUTEP Ltd (0001506184) (Filer)
- PRImmutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026First-in-human Phase I study met its primary endpoint, demonstrating favourable safety and tolerability in healthy volunteers in the single ascending dose part of the studyPhase I data demonstrate statistically significant pharmacodynamic activity at 7 mg/kg in a validated placebo controlled double blinded setting, supporting further clinical investigation in autoimmune diseasesAdditional trial updates will follow in H2 CY2026 SYDNEY, AUSTRALIA, June 04, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapies, today announced it will present first-in-human clinical data for its lead autoimmune
- PRSystemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patientsSYDNEY, AUSTRALIA, May 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announced results from a systematic evaluation of 5 clinical trials of eftilagimod alfa ("efti") an antigen-presenting cell (APC) activator in combination with standard-of-care (SOC) therapies in late-stage cancer patients. In these trials, treatment with 30 mg subcutaneous (SC) efti plus SOC resulted in a significant increase in circulating absolute lymphocyte count (ALC), a blood-based measure of immune activity, compared to SOC alone where this effect was not seen. More important
- SECSEC Form 6-K filed by Immutep Limited6-K - IMMUTEP Ltd (0001506184) (Filer)
- PRImmutep Receives Nasdaq Notice of Bid Price DeficiencySYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), advises that it has received a written notification from The Nasdaq Stock Market LLC (Nasdaq) regarding non-compliance with the Nasdaq minimum bid price requirement. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of US$1.00 per share. Based on the closing bid price of the Company's American Depositary Shares for the 30 consecutive business days ended 24 April 2026, the Company does not currently meet this requirement. The notification has no immediate effect on the listing or trading of the Company's American Depositary Sh
- PRImmutep Quarterly Activities Report Q3 FY26Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trialRoot cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under reviewPhase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions. SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biot
- PRImmutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual MeetingSYDNEY, AUSTRALIA, April 22, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an abstract has been selected for poster presentation at the upcoming 2026 American Society of Clinical Oncology's (ASCO) Annual Meeting, taking place in-person and online from 29 May-2 June 2026 in Chicago, Illinois (United States). The accepted abstract, titled "Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients," will be presented within the Developmental Therapeutics—Immunotherap
- INSIDERSEC Form 3 filed by new insider Boyce Elisabeth Amanda3 - IMMUTEP Ltd (0001506184) (Issuer)
- SECSEC Form 6-K filed by Immutep Limited6-K - IMMUTEP Ltd (0001506184) (Filer)
- PRImmutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue SarcomaSYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for eftilagimod alfa ("efti") for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need. The FDA's Orphan Drug Designation program is designed to encourage development of therapies for rare diseases affecting fewer than 200,000 people in the United States. Benefits of ODD may include regulatory support, potential tax credits, fee exe
- INSIDERSEC Form 3 filed by new insider Voigt Marc3 - IMMUTEP Ltd (0001506184) (Issuer)
IMMP FAQ
6 questionsWhat does Immutep Limited do?
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Âeftilagimod alpha' or Âefti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck...Where does IMMP stock trade?
Immutep Limited (IMMP) is listed on NASDAQ.What sector and industry is IMMP in?
Immutep Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IMMP?
Immutep Limited has had 8 recent analyst actions on file. The most recent action was from Maxim Group: Hold on 2026-03-13.What companies are similar to IMMP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IMMP side-by-side with any of them on Quantisnow.How can I track IMMP on Quantisnow?
Quantisnow aggregates Immutep Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMMP to receive live email and push alerts on every new disclosure.